HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Toni K Choueiri Selected Research

Neoplasms (Cancer)

4/2024Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
3/2024Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes.
3/2024Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes.
2/2024Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma.
2/2024Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model.
1/2024Comparison of outcomes for Hispanic and non-Hispanic patients with advanced renal cell carcinoma in the International Metastatic Renal Cell Carcinoma Database.
1/2024The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
1/2024Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
1/2024Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects.
12/2023PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti-PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Toni K Choueiri Research Topics

Disease

349Renal Cell Carcinoma (Grawitz Tumor)
04/2024 - 12/2003
263Neoplasms (Cancer)
04/2024 - 08/2004
71Prostatic Neoplasms (Prostate Cancer)
12/2023 - 03/2006
43Carcinoma (Carcinomatosis)
12/2022 - 03/2006
42Neoplasm Metastasis (Metastasis)
10/2023 - 03/2006
40Kidney Neoplasms (Kidney Cancer)
01/2024 - 08/2007
25Disease Progression
11/2023 - 12/2010
25Fatigue
10/2021 - 06/2008
20Hypertension (High Blood Pressure)
01/2023 - 06/2008
16Urinary Bladder Neoplasms (Bladder Cancer)
12/2022 - 08/2008
13Hypoxia (Hypoxemia)
10/2023 - 10/2006
11Melanoma (Melanoma, Malignant)
01/2024 - 12/2014
10COVID-19
08/2023 - 01/2020
8Brain Neoplasms (Brain Tumor)
03/2024 - 09/2006
7Adenocarcinoma
11/2022 - 06/2012
7Breast Neoplasms (Breast Cancer)
05/2014 - 08/2004
6Hematologic Neoplasms (Hematological Malignancy)
03/2023 - 12/2003
6Exanthema (Rash)
01/2021 - 08/2004
6Nausea
01/2021 - 05/2010
6Diarrhea
01/2021 - 06/2008
6Anemia
01/2018 - 11/2011
5Hand-Foot Syndrome
01/2023 - 06/2008
5Heart Failure
09/2015 - 02/2011
4Carcinogenesis
11/2023 - 11/2012
4Body Weight (Weight, Body)
05/2023 - 11/2015
4Infections
03/2023 - 09/2005
4Margins of Excision
10/2019 - 11/2011
4Hypothyroidism
01/2018 - 01/2017
4Pneumonia (Pneumonitis)
01/2017 - 07/2012
4Transitional Cell Carcinoma
07/2012 - 04/2010
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2024 - 01/2021
3Sarcoma (Soft Tissue Sarcoma)
02/2024 - 03/2011
3Venous Thromboembolism
01/2023 - 12/2012

Drug/Important Bio-Agent (IBA)

78Sunitinib (Sutent)FDA Link
04/2024 - 01/2008
66Immune Checkpoint InhibitorsIBA
04/2024 - 11/2015
62Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
04/2024 - 10/2006
55Biomarkers (Surrogate Marker)IBA
02/2024 - 01/2013
40NivolumabIBA
01/2024 - 06/2015
37cabozantinibIBA
08/2023 - 11/2015
32AndrogensIBA
01/2022 - 03/2009
30EverolimusFDA Link
01/2023 - 05/2011
28pembrolizumabIBA
04/2024 - 01/2016
27Tyrosine Kinase InhibitorsIBA
10/2023 - 01/2008
22Axitinib (AG 013736)IBA
03/2024 - 06/2008
22IpilimumabIBA
01/2024 - 01/2017
18Prostate-Specific Antigen (Semenogelase)IBA
12/2023 - 03/2009
17Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
10/2022 - 10/2009
16PlatinumIBA
03/2022 - 04/2010
16pazopanibFDA Link
01/2021 - 03/2011
15Bevacizumab (Avastin)FDA Link
01/2023 - 05/2009
15Proteins (Proteins, Gene)FDA Link
01/2023 - 03/2006
14DNA (Deoxyribonucleic Acid)IBA
12/2021 - 11/2012
14Sorafenib (BAY 43-9006)FDA Link
01/2019 - 01/2008
12atezolizumabIBA
01/2023 - 01/2018
12RNA (Ribonucleic Acid)IBA
11/2022 - 07/2014
11lenvatinibIBA
04/2024 - 03/2019
11avelumabIBA
02/2024 - 01/2018
11Cisplatin (Platino)FDA LinkGeneric
01/2021 - 05/2007
11Hemoglobins (Hemoglobin)IBA
01/2018 - 03/2008
10B7-H1 AntigenIBA
01/2022 - 07/2014
10MTOR InhibitorsIBA
01/2022 - 08/2010
10LigandsIBA
11/2020 - 01/2014
9TOR Serine-Threonine KinasesIBA
08/2016 - 06/2009
8Angiogenesis InhibitorsIBA
05/2014 - 10/2006
7Messenger RNA (mRNA)IBA
10/2021 - 08/2014
7Phosphotransferases (Kinase)IBA
10/2018 - 06/2008
6Monoclonal AntibodiesIBA
01/2021 - 11/2015
6ParaffinIBA
12/2018 - 11/2013
6Formaldehyde (Formol)FDA Link
12/2018 - 07/2014
5belzutifanIBA
11/2023 - 01/2021
5Transcription Factors (Transcription Factor)IBA
11/2023 - 10/2009
5Cell-Free Nucleic AcidsIBA
03/2022 - 01/2020
5Alanine Transaminase (SGPT)IBA
01/2022 - 08/2013
5Lipase (Acid Lipase)FDA Link
01/2021 - 08/2016
5temsirolimusFDA Link
01/2020 - 05/2009
5Docetaxel (Taxotere)FDA Link
01/2018 - 07/2011
5Hormones (Hormone)IBA
01/2015 - 08/2004
4Carbonic Anhydrase IXIBA
01/2024 - 05/2009
4Circulating Tumor DNAIBA
11/2023 - 10/2017
4Oxygen (Dioxygen)IBA
08/2023 - 10/2020
4vinflunineIBA
01/2017 - 04/2010
3Programmed Cell Death 1 ReceptorIBA
01/2024 - 02/2018
3AntigensIBA
01/2024 - 01/2016
3Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
09/2023 - 02/2012

Therapy/Procedure

291Therapeutics
04/2024 - 08/2004
45Immunotherapy
03/2024 - 11/2007
37Drug Therapy (Chemotherapy)
03/2024 - 03/2006
34Nephrectomy
10/2023 - 12/2008
20Prostatectomy (Retropubic Prostatectomy)
10/2019 - 11/2008
17Radiotherapy
07/2023 - 08/2008
10Cystectomy
12/2021 - 08/2008
9Brachytherapy
01/2019 - 10/2010
8Castration
01/2023 - 10/2009
7Neoadjuvant Therapy
12/2021 - 10/2012
6Aftercare (After-Treatment)
08/2023 - 02/2011
6Metastasectomy
01/2021 - 02/2011
4Time-to-Treatment
01/2020 - 08/2010
4Adjuvant Chemotherapy
02/2018 - 07/2014
4Lymph Node Excision (Lymph Node Dissection)
01/2018 - 05/2007
4Salvage Therapy
01/2018 - 04/2010